Amifostine
- Generic Name
- Amifostine
- Brand Names
- Ethyol
- Drug Type
- Small Molecule
- Chemical Formula
- C5H15N2O3PS
- CAS Number
- 20537-88-6
- Unique Ingredient Identifier
- ILA426L95O
- Background
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
- Indication
For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.
- Associated Conditions
- Dry Mouth, Nephrotoxicity, Prophylaxis of Radiation proctitis
- Associated Therapies
- -
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer
- Conditions
- Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7Stage II Nasopharyngeal Undifferentiated Carcinoma AJCC v7Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 111
- Registration Number
- NCT00274937
- Locations
- 🇺🇸
Driscoll Children's Hospital, Corpus Christi, Texas, United States
🇺🇸Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)
- Conditions
- Interventions
- First Posted Date
- 2005-12-28
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Mohan Suntharalingam
- Target Recruit Count
- 21
- Registration Number
- NCT00270790
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2005-09-12
- Lead Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Target Recruit Count
- 296
- Registration Number
- NCT00158691
- Locations
- 🇫🇷
Centre Régional de Lutte contre le Cancer de Nantes-Atlantique, Nantes, France
Radiation With Chemotherapy and a Study Drug to the Para-Aortic Nodes in Cervical Cancer
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT00137358
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Amifostine for Head and Neck Irradiation in Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 75
- Registration Number
- NCT00136474
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Randomized Amifostine For SCCHN
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 58
- Registration Number
- NCT00095927
- Locations
- 🇺🇸
Goodall Hospital, Sanford, Maine, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00003143
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-04-09
- Last Posted Date
- 2007-08-21
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 130
- Registration Number
- NCT00081315
- Locations
- 🇺🇸
St. Agnes Health Care, Baltimore, Maryland, United States
🇺🇸Long Island Jewish Medical Center, New Hyde Park, New York, United States
🇺🇸Center for Cancer & Blood Disorders, Bethesda, Maryland, United States
High-dose ICE With Amifostine
- Conditions
- Interventions
- First Posted Date
- 2004-03-31
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00003657
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2012-10-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00078845
- Locations
- 🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.